Shopping Cart
Remove All
Your shopping cart is currently empty
Gaultherin has analgesic, and anti-inflammatory activities.Gaultherin lacks gastric ulcerogenic effect, because of it released salicylate in intestine slowly, not in stomach and it left the cyclooxygenase-1 unaffected, which was the source of cytoprotective prostaglandins in gastric epithelium.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $35 | In Stock | In Stock | |
| 5 mg | $54 | In Stock | In Stock | |
| 10 mg | $83 | In Stock | In Stock | |
| 25 mg | Preferential | In Stock | In Stock | |
| 50 mg | Preferential | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $68 | In Stock | In Stock |
| Description | Gaultherin has analgesic, and anti-inflammatory activities.Gaultherin lacks gastric ulcerogenic effect, because of it released salicylate in intestine slowly, not in stomach and it left the cyclooxygenase-1 unaffected, which was the source of cytoprotective prostaglandins in gastric epithelium. |
| In vitro | The synthesis of Gaultherin (1) and its analogs was carried out to provide 11 glycosides under phase-transfer catalytic conditions. METHODS AND RESULTS: The activities of all synthesized compounds were evaluated by nitric oxide production inhibitory assay in vitro. Methyl 2-O-(4-O-β-d-galactopyranosyl)-β-d-glucopyranosylbenzoate (5f) showed significantly anti-nociceptive and anti-inflammatory effects by the evaluation in vivo. Structure-activity relationships within these compounds were discussed. |
| Molecular Weight | 446.4 |
| Formula | C19H26O12 |
| Cas No. | 490-67-5 |
| Smiles | COC(=O)c1ccccc1O[C@@H]1O[C@H](CO[C@@H]2OC[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O |
| Relative Density. | 1.58g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (112.01 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.48 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.